The Journal of Thoracic and Cardiovascular Surgery
Volume 127, Issue 2 , Pages 355-364 , February 2004

Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

  • Robert E Merritt, MD

      Affiliations

    • Department of Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Reiko E Yamada, BA

      Affiliations

    • Department of Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Ronald G Crystal, MD

      Affiliations

    • Department of Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Robert J Korst, MD

      Affiliations

    • Department of Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, NY, USA
    • Corresponding Author InformationAddress for reprints: Robert J. Korst, MD, Assistant Professor of Cardiothoracic Surgery, Weill Medical College of Cornell University, Department of Cardiothoracic Surgery, M404, 525 East 68th Street, Box 110, New York, NY 10021, USA

Received 1 May 2003 ,Revised 16 July 2003 ,Accepted 17 September 2003.

References 

  1. Agrawal S, Kishore MC. MHC class I gene expression and regulation. J Hematother Stem Cell Res. 2000;9:795–812
  2. Rees RC, Mian S. Selective MHC expression in tumors modulates adaptive and innate antitumor responses. Cancer Immunol Immunother. 1999;48:374–381
  3. Tanaka K, Yoshioka T, Bierberich C, Jay G. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol. 1988;6:359–380
  4. Hiraki A, Kaneshige T, Kiura K, Ueoka H, Yamane H, Tanaka M, et al.  Loss of HLA haplotype in lung cancer cell lines (implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer). Clin Cancer Res. 1999;5:933–936
  5. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 1996;73:148–153
  6. Dammrich J, Muller-Hermelink HK, Mattner A, Buchwald J, Ziffer S. Histocompatibility antigen expression in pulmonary carcinomas as indication of differentiation and special subtypes. Cancer. 1990;65:1942–1954
  7. Sugaya M, Takenoyama M, Osaki T, Yasuda M, Nagashima A, Sugio K, et al.  Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest. 2002;122:282–288
  8. Wroblewski JM, Bixby DL, Borowski C, Yannelli JR. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor associated antigens. Lung Cancer. 2001;33:181–184
  9. AbdAlla EE, Blair GE, Jones RA, Sue-Ling HM, Johnston D. Mechanism of synergy of levamisole and fluorouracil (induction of human leukocyte antigen class I in a colorectal cancer cell line). J Natl Cancer Inst. 1995;87:489–496
  10. Yano T, Fukuyama Y, Yokoyama H, Kuninaka S, Asoh H, Katsuda Y, et al.  HLA class I and class II expression of pulmonary adenocarcinoma cells and influence of interferon gamma. Lung Cancer. 1998;20:185–190
  11. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther. 1999;10:1375–1387
  12. Lee JA, Mahtabifard A, Yamada R, Crystal RG, Korst RJ. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor κB cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors. Clin Cancer Res. 2002;8:3561–3569
  13. Hersh JR, Crystal RG, Bewig B. Modulation of gene expression after replication deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Ther. 1995;2:124–131
  14. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, et al.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to airway epithelium. Cell. 1992;68:143–155
  15. Rosenfeld MA, Sigfried W, Yoshimura K, Yoneyyama K, Fukayama M, Stier LE, et al.  Adenovirus-mediated transfer of a recombinant alpha1-antitrypsin gene to the lung epithelium in vivo. Science. 1991;252:431–434
  16. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus for gene therapy. J Virol. 1996;70:7498–7509
  17. Nakamura T, Takahashi K, Koyanagi M, Yagita H, Okumura K. Activation of a natural killer clone upon target cell binding via CD2. Eur J Immunol. 1991;21:831–834
  18. Noguchi K, Tanimura H, Yamaue H, Iwahashi M, Tsunoda T, Tani M, et al.  Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin. J Cancer Res Clin Oncol. 1997;123:345–351
  19. Lewis J, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, et al.  Evaluation of CD8+ T cell frequencies by the ELISPOT assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer. 2000;87:391–398
  20. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini J-C, et al.  Quantitation of antigen-reactive T cells in peripheral blood by IFN-γ-ELISPOT assay and chromium-release assay (a four-centre comparative trial). J Immunol Methods. 2000;244:81–89
  21. Doherty PC, Knowles BB, Wettstein PJ. Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function. Adv Cancer Res. 1984;42:1–65
  22. Hui KM. Re-expression of major histocompatibility complex (MHC) class I molecules on malignant tumor cells and its effect on host-tumor interaction. BioEssays. 1989;11:22–26
  23. Marrack P, Kappler J. The T-cell repertoire for antigen and MHC. Immunol Today. 1988;9:308–315
  24. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33
  25. Hollinshead A, Stewart TH, Takita H, Dalbow M, Concannon J. Adjuvant specific lung cancer immunotherapy trials. Tumor-associated antigens. Cancer. 1987;60:1249–1262
  26. Blieden TM, McAdam AJ, Foresman MD, Cerosaletti KM, Frelinger FG, Lord EM. Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors. Int J Cancer. 1999;6:82-9
  27. Yamada M, Shiroko T, Kawaguchi Y, et al.  CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors. Int J Cancer. 2001;92:589–599
  28. Al-Moundhri M, O'Brien M, Souberbielle BE. Immunotherapy in lung cancer. Br J Cancer. 1998;78:282–288
  29. Gleave ME, Elhilali M, Fradet Y, Davis I, Vemer P, Saad F, et al.  Interferon gamma-1b compared to placebo in metastatic renal-cell carcinoma. N Engl J Med. 1998;338:1265–1271

☆ These studies were supported, in part, by the Will Rogers Memorial Fund, Los Angeles, Calif; Gen Vec, Inc., Gaithersburg, Md; and grants from The Thoracic Surgery Foundation for Research and Education (R.J.K.) and the American Lung Association (R.J.K.).

PII: S0022-5223(03)01605-2

doi: 10.1016/j.jtcvs.2003.09.007

The Journal of Thoracic and Cardiovascular Surgery
Volume 127, Issue 2 , Pages 355-364 , February 2004

Article Tools

* Image Usage & Resolution